Remlarsen is under clinical development by Viridian Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Remlarsen’s likelihood of approval (LoA) and phase transition for Keloids took place on 21 Jan 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Remlarsen Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Remlarsen overview

Remlarsen (MRG-201) is under development for the treatment of pathological fibrosis including cutaneous fibrosis (keloid), idiopathic pulmonary fibrosis, ocular fibrosis (corneal ulcers) and other fibrotic indications. It is administered through intradermal injection. The drug candidate is an oligonucleotide. It targets miR-29b which represses expression of collagen. The drug candidate is based on locked nucleic acid (LNA) drug platform. It was also under development for the treatment of cardiac fibrosis.

Viridian Therapeutics overview

Viridian Therapeutics (Viridian), formerly Miragen Therapeutics Inc is a clinical stage biopharmaceutical company. The company discovers and develops novel RNA-based therapeutics, with a core focus on therapeutic antibodies and their roles in diseases. It focuses on thyroid eye disease and cardiovascular disease areas. Viridian lead pipeline products candidates include VRDN-001 (Intravenous) for treating thyroid eye disease (TED); and VRDN-002 (Subcutaneous), an inhibitor using half-life technology for treating thyroid eye disease (TED). The company has been depending on the third parties for the manufacturing and supply of the products. Viridian is headquartered in Boulder, Colorado, the US.

Quick View Remlarsen LOA Data

Report Segments
  • Innovator
Drug Name
  • Remlarsen
Administration Pathway
  • Intradermal
Therapeutic Areas
  • Cardiovascular
  • Dermatology
  • Ophthalmology
  • Respiratory
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.